Loading
A phase 1/2 trial of Toripalimab in sarcomas and uterine sarcoma, run by STORM Therapeutics LTD, now recruiting.
STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas is a phase 1/2 interventional study registered as NCT06975293 by STORM Therapeutics LTD, with 107 participants planned, started 2025-05-05 and due to reach its primary completion in 2027-12-29. Interventions recorded: STC-15 in combination with toripalimab and STC-15 monotherapy.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Toripalimab, Sarcomas (soft tissue, bone, GIST), Immune checkpoint inhibitors and the tag pipeline.
Shares Toripalimab, Immune checkpoint inhibitors and the tag pipeline.
Shares Toripalimab, Immune checkpoint inhibitors and the tag pipeline.
Shares Toripalimab, Immune checkpoint inhibitors and the tag pipeline.
Shares Toripalimab, Immune checkpoint inhibitors and the tag pipeline.
Shares Toripalimab, Immune checkpoint inhibitors and the tag pipeline.
Shares Toripalimab, Immune checkpoint inhibitors and the tag pipeline.
Shares Toripalimab, Immune checkpoint inhibitors and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/